1
|
Bernard C, Joly Kukla C, Rakotoarivony I, Duhayon M, Stachurski F, Huber K, Giupponi C, Zortman I, Holzmuller P, Pollet T, Jeanneau M, Mercey A, Vachiery N, Lefrançois T, Garros C, Michaud V, Comtet L, Despois L, Pourquier P, Picard C, Journeaux A, Thomas D, Godard S, Moissonnier E, Mely S, Sega M, Pannetier D, Baize S, Vial L. Detection of Crimean-Congo haemorrhagic fever virus in Hyalomma marginatum ticks, southern France, May 2022 and April 2023. Euro Surveill 2024; 29:2400023. [PMID: 38333936 PMCID: PMC10853980 DOI: 10.2807/1560-7917.es.2024.29.6.2400023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 02/01/2024] [Indexed: 02/10/2024] Open
Abstract
Crimean-Congo haemorrhagic fever (CCHF), a potentially severe zoonotic viral disease causing fever and haemorrhagic manifestations in humans. As the Crimean-Congo haemorrhagic fever virus (CCHFV) has been detected in ticks in Spain and antibodies against the virus in ruminant sera in Corsica, it was necessary to know more about the situation in France. In 2022-2023, CCHFV was detected in 155 ticks collected from horses and cattle in southern France.
Collapse
Affiliation(s)
- Célia Bernard
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Charlotte Joly Kukla
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
- Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), INRAE, Ecole Nationale Vétérinaire d'Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, France
| | - Ignace Rakotoarivony
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Maxime Duhayon
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Frédéric Stachurski
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Karine Huber
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Carla Giupponi
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Iyonna Zortman
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Philippe Holzmuller
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Thomas Pollet
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Mélanie Jeanneau
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Alice Mercey
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Nathalie Vachiery
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | | | - Claire Garros
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | - Vincent Michaud
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| | | | | | | | - Caroline Picard
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur - Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Institut national de la santé et de la recherche médicale (INSERM) U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Alexandra Journeaux
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur - Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Institut national de la santé et de la recherche médicale (INSERM) U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Damien Thomas
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Laboratoire P4 INSERM Jean Mérieux, INSERM Lyon, France
| | - Sabine Godard
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Laboratoire P4 INSERM Jean Mérieux, INSERM Lyon, France
| | - Elodie Moissonnier
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Laboratoire P4 INSERM Jean Mérieux, INSERM Lyon, France
| | - Stéphane Mely
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Laboratoire P4 INSERM Jean Mérieux, INSERM Lyon, France
| | - Manon Sega
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Laboratoire P4 INSERM Jean Mérieux, INSERM Lyon, France
| | - Delphine Pannetier
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Laboratoire P4 INSERM Jean Mérieux, INSERM Lyon, France
| | - Sylvain Baize
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, France
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur - Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Institut national de la santé et de la recherche médicale (INSERM) U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Laurence Vial
- Centre de coopération internationale en recherche agronomique pour le développement (CIRAD), University of Montpellier (UMR) Animal Santé Territoires Risques Écosystèmes (ASTRE), Montpellier, France
- ASTRE UMR, CIRAD, Institut national de la recherche agronomique (INRAE), Montpellier, France
| |
Collapse
|
2
|
Garbuglia AR, Lapa D, Pauciullo S, Raoul H, Pannetier D. Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries. Viruses 2023; 15:2062. [PMID: 37896839 PMCID: PMC10612039 DOI: 10.3390/v15102062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 10/02/2023] [Accepted: 10/05/2023] [Indexed: 10/29/2023] Open
Abstract
Nipah virus (NiV) is a paramyxovirus responsible for a high mortality rate zoonosis. As a result, it has been included in the list of Blueprint priority pathogens. Bats are the main reservoirs of the virus, and different clinical courses have been described in humans. The Bangladesh strain (NiV-B) is often associated with severe respiratory disease, whereas the Malaysian strain (NiV-M) is often associated with severe encephalitis. An early diagnosis of NiV infection is crucial to limit the outbreak and to provide appropriate care to the patient. Due to high specificity and sensitivity, qRT-PCR is currently considered to be the optimum method in acute NiV infection assessment. Nasal swabs, cerebrospinal fluid, urine, and blood are used for RT-PCR testing. N gene represents the main target used in molecular assays. Different sensitivities have been observed depending on the platform used: real-time PCR showed a sensitivity of about 103 equivalent copies/reaction, SYBRGREEN technology's sensitivity was about 20 equivalent copies/reaction, and in multiple pathogen card arrays, the lowest limit of detection (LOD) was estimated to be 54 equivalent copies/reaction. An international standard for NiV is yet to be established, making it difficult to compare the sensitivity of the different methods. Serological assays are for the most part used in seroprevalence studies owing to their lower sensitivity in acute infection. Due to the high epidemic and pandemic potential of this virus, the diagnosis of NiV should be included in a more global One Health approach to improve surveillance and preparedness for the benefit of public health. Some steps need to be conducted in the diagnostic field in order to become more efficient in epidemic management, such as development of point-of-care (PoC) assays for the rapid diagnosis of NiV.
Collapse
Affiliation(s)
- Anna Rosa Garbuglia
- Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy; (D.L.); (S.P.)
| | - Daniele Lapa
- Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy; (D.L.); (S.P.)
| | - Silvia Pauciullo
- Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy; (D.L.); (S.P.)
| | - Hervé Raoul
- French National Agency for Research on AIDS—Emerging Infectious Diseases (ANRS MIE), Maladies Infectieuses Émergentes, 75015 Paris, France;
| | - Delphine Pannetier
- Institut National de la Santé et de la Recherche Médicale, Jean Mérieux BSL4 Laboratory, 69002 Lyon, France;
| |
Collapse
|
3
|
Yadouleton A, Picard C, Rieger T, Loko F, Cadar D, Kouthon EC, Job EO, Bankolé H, Oestereich L, Gbaguidi F, Pahlman M, Becker-Ziaja B, Journeaux A, Pannetier D, Mély S, Mundweiler S, Thomas D, Kohossi L, Saizonou R, Kakaï CG, Da Silva M, Kossoubedie S, Kakonku AL, M'Pelé P, Gunther S, Baize S, Fichet-Calvet E. Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus. Emerg Microbes Infect 2021; 9:1761-1770. [PMID: 32723007 PMCID: PMC7473144 DOI: 10.1080/22221751.2020.1796528] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We report two outbreaks of Lassa fever that occurred in Benin in 2014 and 2016 with 20 confirmed cases and 50% (10/20) mortality. Benin was not previously considered to be an endemic country for Lassa fever, resulting in a delay to diagnose the disease and its human transmission. Molecular investigations showed the viral genomes to be similar to that of the Togo strain, which is genetically very different from other known strains and confirms the existence of a new lineage. Endemic circulation of Lassa virus in a new territory and the genetic diversity thus confirm that this virus represents a growing threat for West African people. Given the divergence of the Benin strain from the prototypic Josiah Sierra Leone strain frequently used to generate vaccine candidates, the efficacy of vaccine candidates should also be demonstrated with this strain.
Collapse
Affiliation(s)
| | - Caroline Picard
- Virology Department, Institut Pasteur CNR des fièvres hémorragiques virales (CNR FHV), Lyon, France
| | - Toni Rieger
- Virology Department, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany
| | | | - Daniel Cadar
- Virology Department, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany
| | | | | | | | - Lisa Oestereich
- Virology Department, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany
| | | | - Meike Pahlman
- Virology Department, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Beate Becker-Ziaja
- Virology Department, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany
| | | | | | - Stéphane Mély
- INSERM - Jean Mérieux BSL4Laboratory, CNR FHV, Lyon, France
| | | | - Damien Thomas
- INSERM - Jean Mérieux BSL4Laboratory, CNR FHV, Lyon, France
| | | | | | | | | | | | | | | | - Stephan Gunther
- Virology Department, Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Sylvain Baize
- Laboratoire des Fièvres Hémorragiques Virales, Cotonou, Benin
| | | |
Collapse
|
4
|
Thom R, Tipton T, Strecker T, Hall Y, Akoi Bore J, Maes P, Raymond Koundouno F, Fehling SK, Krähling V, Steeds K, Varghese A, Bailey G, Matheson M, Kouyate S, Coné M, Moussa Keita B, Kouyate S, Richard Ablam A, Laenen L, Vergote V, Guiver M, Timothy J, Atkinson B, Ottowell L, Richards KS, Bosworth A, Longet S, Mellors J, Pannetier D, Duraffour S, Muñoz-Fontela C, Sow O, Koivogui L, Newman E, Becker S, Sprecher A, Raoul H, Hiscox J, Henao-Restrepo AM, Sakoba K, Magassouba N, Günther S, Kader Konde M, Carroll MW. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. Lancet Infect Dis 2021; 21:507-516. [PMID: 33065039 PMCID: PMC7553754 DOI: 10.1016/s1473-3099(20)30736-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 08/12/2020] [Accepted: 08/24/2020] [Indexed: 01/04/2023]
Abstract
BACKGROUND The 2013-16 Ebola virus disease epidemic in west Africa caused international alarm due to its rapid and extensive spread resulting in a significant death toll and social unrest within the affected region. The large number of cases provided an opportunity to study the long-term kinetics of Zaire ebolavirus-specific immune response of survivors in addition to known contacts of those infected with the virus. METHODS In this observational cohort study, we worked with leaders of Ebola virus disease survivor associations in two regions of Guinea, Guéckédou and Coyah, to recruit survivors of Ebola virus disease, contacts from households of individuals known to have had Ebola virus disease, and individuals who were not knowingly associated with infected individuals or had not had Ebola virus disease symptoms to serve as negative controls. We did Zaire ebolavirus glycoprotein-specific T cell analysis on peripheral blood mononuclear cells (PBMCs) on location in Guinea and transported plasma and PBMCs back to Europe for antibody quantification by ELISA, functional neutralising antibody analysis using live Zaire ebolavirus, and T cell phenotype studies. We report on the longitudinal cellular and humoral response among Ebola virus disease survivors and highlight potentially paucisymptomatic infection. FINDINGS We recruited 117 survivors of Ebola virus disease, 66 contacts, and 23 negative controls. The mean neutralising antibody titre among the Ebola virus disease survivors 3-14 months after infection was 1/174 (95% CI 1/136-1/223). Individual results varied greatly from 1/10 to more than 1/1000 but were on average ten times greater than that induced after 1 month by single dose Ebola virus vaccines. Following reactivation with glycoprotein peptide, the mean T cell responses among 116 Ebola virus disease survivors as measured by ELISpot was 305 spot-forming units (95% CI 257-353). The dominant CD8+ polyfunctional T cell phenotype, as measured among 53 Ebola virus disease survivors, was interferon γ+, tumour necrosis factor+, interleukin-2-, and the mean response was 0·046% of total CD8+ T cells (95% CI 0·021-0·071). Additionally, both neutralising antibody and T cell responses were detected in six (9%) of 66 Ebola virus disease contacts. We also noted that four (3%) of 117 individuals with Ebola virus disease infections did not have circulating Ebola virus-specific antibodies 3 months after infection. INTERPRETATION The continuous high titre of neutralising antibodies and increased T cell response might support the concept of long-term protective immunity in survivors. The existence of antibody and T cell responses in contacts of individuals with Ebola virus disease adds further evidence to the existence of sub-clinical Ebola virus infection. FUNDING US Food & Drug Administration, Horizon 2020 EU EVIDENT, Wellcome, UK Department for International Development. TRANSLATION For the French translation of the abstract see Supplementary Materials section.
Collapse
MESH Headings
- Adolescent
- Adult
- Antibodies, Viral/blood
- Antibodies, Viral/immunology
- Antibodies, Viral/isolation & purification
- Child
- Child, Preschool
- Ebolavirus/immunology
- Ebolavirus/pathogenicity
- Epidemics
- Female
- Guinea/epidemiology
- Hemorrhagic Fever, Ebola/blood
- Hemorrhagic Fever, Ebola/immunology
- Hemorrhagic Fever, Ebola/transmission
- Hemorrhagic Fever, Ebola/virology
- Humans
- Immunity, Cellular
- Immunity, Humoral
- Infant
- Infant, Newborn
- Longitudinal Studies
- Male
- Middle Aged
- Survivors/statistics & numerical data
- T-Lymphocytes/immunology
- Time Factors
- Young Adult
Collapse
Affiliation(s)
- Ruth Thom
- National Infection Service, Public Health England, Porton Down, UK
| | - Thomas Tipton
- National Infection Service, Public Health England, Porton Down, UK
| | - Thomas Strecker
- Institute of Virology, Philipps University of Marburg, Marburg, Germany
| | - Yper Hall
- National Infection Service, Public Health England, Porton Down, UK
| | - Joseph Akoi Bore
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea; Ministry of Health Guinea, Conakry, Guinea
| | - Piet Maes
- Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
| | - Fara Raymond Koundouno
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Ministry of Health Guinea, Conakry, Guinea
| | | | - Verena Krähling
- Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, Marburg, Germany
| | - Kimberley Steeds
- National Infection Service, Public Health England, Porton Down, UK
| | - Anitha Varghese
- National Infection Service, Public Health England, Porton Down, UK
| | - Graham Bailey
- Biodiscovery Institute, School of Medicine, University of Nottingham, UK
| | - Mary Matheson
- National Infection Service, Public Health England, Porton Down, UK
| | - Saidou Kouyate
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea
| | - Moussa Coné
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea
| | - Balla Moussa Keita
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea
| | - Sekou Kouyate
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea
| | - Amento Richard Ablam
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea
| | - Lies Laenen
- Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
| | | | - Malcolm Guiver
- Public Health Laboratory, National Infection Service, Public Health England, Manchester Royal Infirmary, Manchester, UK
| | - Joseph Timothy
- Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK
| | - Barry Atkinson
- National Infection Service, Public Health England, Porton Down, UK
| | - Lisa Ottowell
- National Infection Service, Public Health England, Porton Down, UK
| | - Kevin S Richards
- National Infection Service, Public Health England, Porton Down, UK
| | - Andrew Bosworth
- National Infection Service, Public Health England, Porton Down, UK
| | - Stephanie Longet
- National Infection Service, Public Health England, Porton Down, UK
| | - Jack Mellors
- National Infection Service, Public Health England, Porton Down, UK; Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
| | | | - Sophie Duraffour
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - César Muñoz-Fontela
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Oumou Sow
- National Ethics Committee for Health Research, Conakry, Guinea
| | | | - Edmund Newman
- National Infection Service, Public Health England, Porton Down, UK
| | - Stephan Becker
- Institute of Virology, Philipps University of Marburg, Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, Marburg, Germany
| | | | - Herve Raoul
- P4 Jean Mérieux-Inserm Laboratory, Lyon, France
| | - Julian Hiscox
- Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
| | | | - Keita Sakoba
- Projet Laboratoire Fièvres Hémorragiques, Conakry, Guinea
| | | | - Stephan Günther
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
| | - Mandy Kader Konde
- Center for Training and Research on Priority Diseases including Malaria in Guinea, Conakry, Guinea
| | - Miles W Carroll
- National Infection Service, Public Health England, Porton Down, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
| |
Collapse
|
5
|
Racine T, Denizot M, Pannetier D, Nguyen L, Pasquier A, Raoul H, Saluzzo JF, Kobinger G, Veas F, Herbreteau CH. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2. J Infect Dis 2020; 220:41-45. [PMID: 30852585 DOI: 10.1093/infdis/jiz068] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Accepted: 02/11/2019] [Indexed: 12/21/2022] Open
Abstract
There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab')2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab')2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab')2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab')2 offers a potentially efficient therapeutic approach against EBOV disease in humans.
Collapse
Affiliation(s)
- Trina Racine
- Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Canada.,Department of Medical Microbiology, Winnipeg, Canada.,Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Canada
| | | | | | | | | | - Hervé Raoul
- INSERM, Jean Mérieux BSL-4 Laboratory, Lyon, France
| | | | - Gary Kobinger
- Department of Medical Microbiology, Winnipeg, Canada.,Department of Immunology, University of Manitoba, Winnipeg, Canada.,Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Canada.,Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
| | - Francisco Veas
- Institut de Recherche pour le Développement, UMR-Ministère de la Défense, Faculté de Pharmacie, Université de Montpellier, France
| | | |
Collapse
|
6
|
Couturier C, Wada A, Louis K, Mistretta M, Beitz B, Povogui M, Ripaux M, Mignon C, Werle B, Lugari A, Pannetier D, Godard S, Bocquin A, Mely S, Béavogui I, Hébélamou J, Leuenberger D, Leissner P, Yamamoto T, Lécine P, Védrine C, Chaix J. Characterization and analytical validation of a new antigenic rapid diagnostic test for Ebola virus disease detection. PLoS Negl Trop Dis 2020; 14:e0007965. [PMID: 31951615 PMCID: PMC6992227 DOI: 10.1371/journal.pntd.0007965] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 01/30/2020] [Accepted: 11/27/2019] [Indexed: 01/16/2023] Open
Abstract
Hemorrhagic fever outbreaks are difficult to diagnose and control in part because of a lack of low-cost and easily accessible diagnostic structures in countries where etiologic agents are present. Furthermore, initial clinical symptoms are common and shared with other endemic diseases such as malaria or typhoid fever. Current molecular diagnostic methods such as polymerase chain reaction require trained personnel and laboratory infrastructure, hindering diagnostics at the point of need, particularly in outbreak settings. Therefore, rapid diagnostic tests such as lateral flow can be broadly deployed and are typically well-suited to rapidly diagnose hemorrhagic fever viruses, such as Ebola virus. Early detection and control of Ebola outbreaks require simple, easy-to-use assays that can detect very low amount of virus in blood. Here, we developed and characterized an immunoassay test based on immunochromatography coupled to silver amplification technology to detect the secreted glycoprotein of EBOV. The glycoprotein is among the first viral proteins to be detected in blood. This strategy aims at identifying infected patients early following onset of symptoms by detecting low amount of sGP protein in blood samples. The limit of detection achieved by this sGP-targeted kit is 2.2 x 104 genome copies/ml in plasma as assayed in a monkey analytical cohort. Clinical performance evaluation showed a specificity of 100% and a sensitivity of 85.7% when evaluated with plasma samples from healthy controls and patients infected with Zaire Ebola virus from Macenta, Guinea. This rapid and accurate diagnostic test could therefore be used in endemic countries for early detection of infected individuals in point of care settings. Moreover, it could also support efficient clinical triage in hospitals or clinical centers and thus reducing transmission rates to prevent and better manage future severe outbreaks. Ebola virus disease is a severe disease caused by Ebola virus, a member of the filovirus family, which occurs in humans and other primates. Ebola is believed to be zoonotic, however the natural reservoir is unknown. Overlapping symptoms with other endemic diseases, such as malaria and cholera, make accurate diagnostic challenging. Outbreaks of Ebola have been widespread as the consequence of the absence of available rapid, sensitive, specific, robust, and affordable licensed diagnostic test in remote areas, where outbreaks usually start. Here we have established and validated a rapid diagnostic test, which is fast, sensitive, specific, efficient, affordable, and user-friendly. Its analytical characteristics make it suitable for clinical management during Ebola virus outbreaks in remote areas. Of interest, this rapid diagnostic test detects the presence of an early viral antigen, the secreted glycoprotein, found in blood of patients shortly after infection, suggesting that it could be used to identify infected patients shortly after onset of symptoms.
Collapse
Affiliation(s)
| | - Atsuhiko Wada
- FUJIFILM, Ushijima, Kaisei-machi, Ashigarakami-gun Kanagawa, Japan
| | | | | | | | - Moriba Povogui
- Centre de Recherche Et de Formation en Infectiologie de Guinée (CERFIG), République de Guinée
| | | | | | | | | | | | | | - Anne Bocquin
- INSERM Jean Mérieux BSL4 Laboratory, LYON, France
| | | | - Ismaël Béavogui
- CHRS Macenta, c/o Mission Philafricaine, Conakry, République de Guinée
| | - Jean Hébélamou
- CHRS Macenta, c/o Mission Philafricaine, Conakry, République de Guinée
| | - David Leuenberger
- CHRS Macenta, c/o Mission Philafricaine, Conakry, République de Guinée
| | | | - Takeshi Yamamoto
- FUJIFILM, Ushijima, Kaisei-machi, Ashigarakami-gun Kanagawa, Japan
| | | | | | | |
Collapse
|
7
|
Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep 2017. [PMID: 28642489 PMCID: PMC5481440 DOI: 10.1038/s41598-017-03910-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EVD). In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb. After promising results in the guinea pig model of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBOV infection. To ensure stringent therapeutic testing conditions to replicate likely clinical usage, EBOTAb was first delivered 1, 2 or 3 days post-challenge with a lethal dose of EBOV. Results showed a protective effect of EBOTAb given post-exposurally, with survival rates decreasing with increasing time after challenge. Viremia results demonstrated that EBOTAb resulted in a decreased circulation of EBOV in the bloodstream. Additionally, assay of liver enzymes and histology analysis of local tissues identified differences between EBOTAb-treated and untreated groups. The results presented demonstrate that EBOTAb conferred protection against EBOV when given post-exposure and should be explored and developed further as a potential intervention strategy for future outbreaks, which are likely to occur.
Collapse
Affiliation(s)
- Stuart D Dowall
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | - Frédéric Jacquot
- Laboratoire P4, INSERM Jean Merieux, 21 Avenue Tony Garnier, Lyon, France
| | - John Landon
- MicroPharm Ltd, Station Road, Newcastle Emlyn, Dyfed, SA38 9BY, UK
| | - Emma Rayner
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | - Graham Hall
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | | | - Hervé Raoul
- Laboratoire P4, INSERM Jean Merieux, 21 Avenue Tony Garnier, Lyon, France
| | - Delphine Pannetier
- Laboratoire P4, INSERM Jean Merieux, 21 Avenue Tony Garnier, Lyon, France
| | - Ian Cameron
- MicroPharm Ltd, Station Road, Newcastle Emlyn, Dyfed, SA38 9BY, UK
| | - Ruth Coxon
- MicroPharm Ltd, Station Road, Newcastle Emlyn, Dyfed, SA38 9BY, UK
| | | | - Roger Hewson
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | - Miles W Carroll
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
| |
Collapse
|
8
|
Vernet MA, Reynard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Rives M, Georges N, Garcia-Bonnet N, Sylla AI, Grovogui P, Kerherve JY, Savio C, Savio-Coste S, de Séverac ML, Zloczewski P, Linares S, Harouna S, Abdoul BM, Petitjean F, Samake N, Shepherd S, Kinda M, Koundouno FR, Joxe L, Mateo M, Lecine P, Page A, Tchamdja TM, Schoenhals M, Barbe S, Simon B, Tran-Minh T, Longuet C, L'Hériteau F, Baize S. Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight 2017; 2:e88864. [PMID: 28352651 DOI: 10.1172/jci.insight.88864] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND. The pathogenesis of Ebola virus (EBOV) disease (EVD) is poorly characterized. The establishment of well-equipped diagnostic laboratories close to Ebola treatment centers (ETCs) has made it possible to obtain relevant virological and biological data during the course of EVD and to assess their association with the clinical course and different outcomes of the disease. METHODS. We were responsible for diagnosing EBOV infection in patients admitted to two ETCs in forested areas of Guinea. The pattern of clinical signs was recorded, and an etiological diagnosis was established by RT-PCR for EBOV infection or a rapid test for malaria and typhoid fever. Biochemical analyses were also performed. RESULTS. We handled samples from 168 patients between November 29, 2014, and January 31, 2015; 97 patients were found to be infected with EBOV, with Plasmodium falciparum coinfection in 18%. Overall mortality for EVD cases was 58%, rising to 86% if P. falciparum was also present. Viral load was higher in fatal cases of EVD than in survivors, and fatal cases were associated with higher aspartate aminotransferase (AST) and alanine aminotransferase (ALT), C-reactive protein (CRP), and IL-6 levels. Furthermore, regardless of outcome, EVD was characterized by higher creatine kinase (CPK), amylase, and creatinine levels than in febrile patients without EVD, with higher blood urea nitrogen (BUN) levels in fatal cases of EVD only. CONCLUSION. These findings suggest that a high viral load at admission is a marker of poor EVD prognosis. In addition, high AST, ALT, CRP, and IL-6 levels are associated with a fatal outcome of EVD. Damage to the liver and other tissues, with massive rhabdomyolysis and, probably, acute pancreatitis, is associated with EVD and correlated with disease severity. Finally, biochemical analyses provide substantial added value at ETCs, making it possible to improve supportive rehydration and symptomatic care for patients. FUNDING. The French Ministry of Foreign Affairs, the Agence Française de Développement, and Institut Pasteur.
Collapse
Affiliation(s)
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Alexandra Fizet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Justine Schaeffer
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | | | - Jeremie Guedj
- INSERM, Infection, Antimicrobials, Modelling, Evolution, UMR 1137, Université Paris Diderot, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Paris, France
| | - Max Rives
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Nadia Georges
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Nathalie Garcia-Bonnet
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | | | - Péma Grovogui
- Ministère de la Santé, Conakry, République de Guinée
| | - Jean-Yves Kerherve
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Christophe Savio
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Sylvie Savio-Coste
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Marie-Laure de Séverac
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Philippe Zloczewski
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Sandrine Linares
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | - Souley Harouna
- Alliance for International Medical Action, Montreuil, France
| | | | | | - Nenefing Samake
- Alliance for International Medical Action, Montreuil, France
| | - Susan Shepherd
- Alliance for International Medical Action, Montreuil, France
| | - Moumouni Kinda
- Alliance for International Medical Action, Montreuil, France
| | | | - Ludovic Joxe
- Alliance for International Medical Action, Montreuil, France
| | - Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | | | - Audrey Page
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Tang Maleki Tchamdja
- Etablissement de Préparation et de Réponse aux Urgences Sanitaires, Ministère de la Santé, Paris, France
| | | | - Solenne Barbe
- Alliance for International Medical Action, Montreuil, France
| | | | | | | | | | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| |
Collapse
|
9
|
Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 2016; 13:e1002009. [PMID: 27046271 PMCID: PMC4821578 DOI: 10.1371/journal.pmed.1002009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
[This corrects the article DOI: 10.1371/journal.pmed.1001967.].
Collapse
|
10
|
Reusken C, Niedrig M, Pas S, Anda P, Baize S, Charrel R, Di Caro A, Drosten C, Fernandez-Garcia MD, Franco L, Gunther S, Leparc-Goffart I, Martina B, Pannetier D, Papa A, Sanchez-Seco MP, Vapalahti O, Koopmans M. Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014. J Clin Virol 2015; 62:124-34. [DOI: 10.1016/j.jcv.2014.11.007] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25. [PMID: 24738640 DOI: 10.1056/nejmoa1404505] [Citation(s) in RCA: 910] [Impact Index Per Article: 91.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In March 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Full-length genome sequencing and phylogenetic analysis showed that EBOV from Guinea forms a separate clade in relationship to the known EBOV strains from the Democratic Republic of Congo and Gabon. Epidemiologic investigation linked the laboratory-confirmed cases with the presumed first fatality of the outbreak in December 2013. This study demonstrates the emergence of a new EBOV strain in Guinea.
Collapse
Affiliation(s)
- Sylvain Baize
- The authors' affiliations are listed in the Appendix
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Pannetier D, Reynard S, Russier M, Carnec X, Baize S. Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. PLoS Negl Trop Dis 2014; 8:e2637. [PMID: 24421914 PMCID: PMC3888467 DOI: 10.1371/journal.pntd.0002637] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 11/26/2013] [Indexed: 11/18/2022] Open
Abstract
The pathogenesis of Lassa fever (LF), a hemorrhagic fever endemic to West Africa, remains unclear. We previously compared Lassa virus (LASV) with its genetically close, but nonpathogenic homolog Mopeia virus (MOPV) and demonstrated that the strong activation of antigen-presenting cells (APC), including type I IFN production, observed in response to MOPV probably plays a crucial role in controlling infection. We show here that human macrophages (MP) produce large amounts of CC and CXC chemokines in response to MOPV infection, whereas dendritic cells (DC) release only moderate amounts of CXC chemokines. However, in the presence of autologous T cells, DCs produced CC and CXC chemokines. Chemokines were produced in response to type I IFN synthesis, as the levels of both mediators were strongly correlated and the neutralization of type I IFN resulted in an inhibition of chemokine production. By contrast, LASV induced only low levels of CXCL-10 and CXCL-11 production. These differences in chemokine production may profoundly affect the generation of virus-specific T-cell responses and may therefore contribute to the difference of pathogenicity between these two viruses. In addition, a recombinant LASV (rLASV) harboring the NP-D389A/G392A mutations, which abolish the inhibition of type I IFN response by nucleoprotein (NP), induced the massive synthesis of CC and CXC chemokines in both DC and MP, confirming the crucial role of arenavirus NP in immunosuppression and pathogenicity. Finally, we confirmed, using PBMC samples and lymph nodes obtained from LASV-infected cynomolgus monkeys, that LF was associated with high levels of CXC chemokine mRNA synthesis, suggesting that the very early synthesis of these mediators may be correlated with a favourable outcome. Lassa virus (LASV) causes a viral hemorrhagic fever that affects about 300,000 people and leads to 5,000 deaths annually. Lassa fever (LF) is a public health problem in West Africa, where it is endemic, because of the number of cases, deaths and disabling effects. There is no vaccine against LASV and the only treatment, ribavirin, is not useful in the field. Little is known about the pathogenesis and immune responses associated with LF. Chemokines are involved in the induction of immunity and attraction of immune cells to inflamed sites. We compared the ability of antigen-presenting cells to produce chemokines in response to infection with LASV, the closely related but nonpathogenic Mopeia virus (MOPV) and a LASV unable to inhibit the type I IFN response due to mutations in its nucleoprotein gene. We found that MOPV and the mutant LASV, but not wild-type LASV, strongly induced CC and CXC chemokine production by dendritic cells and macrophages, in a type I IFN-dependent manner. We confirmed in cynomolgus monkeys that these mediators probably play a role during LF. These results highlight the role of innate immunity in LF control and provide insight into the mechanisms leading to survival or death after infection.
Collapse
Affiliation(s)
- Delphine Pannetier
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Laboratoire P4 Inserm-Jean Mérieux, US003, Lyon, France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Marion Russier
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Xavier Carnec
- Unité de Génétique Moléculaire des Bunyavirus, Institut Pasteur, Paris, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
- * E-mail:
| |
Collapse
|
13
|
Russier M, Pannetier D, Baize S. La fièvre de Lassa : réponses immunes et pathogenèse. Virologie (Montrouge) 2012; 16:390-401. [PMID: 31910557 DOI: 10.1684/vir.2012.0472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Lassa fever is a hemorrhagic fever endemic to West Africa and caused by Lassa virus, an Old-World arenavirus. It may be fatal, but most patients recover from acute disease and some experience asymptomatic infection. The immune mechanisms associated with these different outcomes have not yet been fully elucidated, but considerable progress has recently been made, through the use of in vitro human models and non-human primates, the only relevant animal model that mimics the pathophysiology and immune responses induced in patients. We discuss here the roles of the various components of the innate and adaptive immune systems in Lassa virus infection and in the control of viral replication and pathogenesis.
Collapse
Affiliation(s)
- Marion Russier
- Institut Pasteur, unité de biologie des infections virales émergentes, 21, avenue Tony-Garnier, 69365 Lyon, France
| | - Delphine Pannetier
- Laboratoire P4 Jean-Mérieux - Inserm, 21, avenue Tony-Garnier, 69365 Lyon, France
| | - Sylvain Baize
- Institut Pasteur, unité de biologie des infections virales émergentes, 21, avenue Tony-Garnier, 69365 Lyon, France
| |
Collapse
|
14
|
Abstract
Lassa fever is a hemorrhagic fever endemic to West Africa and caused by Lassa virus, an Old World arenavirus. It may be fatal, but most patients recover from acute disease and some experience asymptomatic infection. The immune mechanisms associated with these different outcomes have not yet been fully elucidated, but considerable progress has recently been made, through the use of in vitro human models and nonhuman primates, the only relevant animal model that mimics the pathophysiology and immune responses induced in patients. We discuss here the roles of the various components of the innate and adaptive immune systems in Lassa virus infection and in the control of viral replication and pathogenesis.
Collapse
Affiliation(s)
- Marion Russier
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 21 avenue Tony Garnier, 69365 Lyon, France;
| | - Delphine Pannetier
- Laboratoire P4 Jean Mérieux-Inserm, 21 avenue Tony Garnier, 69365 Lyon, France;
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 21 avenue Tony Garnier, 69365 Lyon, France;
- Author to whom correspondence should be addressed; ; Tel.: +33-4-3728-2440; Fax: +33-4-3728-2441
| |
Collapse
|
15
|
Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V, Baize S. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol 2011; 85:8293-306. [PMID: 21632749 PMCID: PMC3147965 DOI: 10.1128/jvi.02120-10] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2010] [Accepted: 05/23/2011] [Indexed: 12/14/2022] Open
Abstract
The events leading to death in severe cases of Lassa fever (LF) are unknown. Fatality seems to be linked to high viremia and immunosuppression, and cellular immunity, rather than neutralizing antibodies, appears to be essential for survival. We previously compared Lassa virus (LV) with its genetically close but nonpathogenic homolog Mopeia virus (MV), which was used to model nonfatal LF. We showed that strong and early activation of antigen-presenting cells (APC) may play a crucial role in controlling infection. Here we developed an in vitro model of dendritic-cell (DC)-T-cell coculture in order to characterize human T-cell responses induced by MV- or LV-infected DCs. Our results show very different responses to infection with LV and MV. MV strongly and durably stimulated CD8(+) and CD4(+) T cells, showing early and high activation, a strong proliferative response, and acquisition of effector and memory phenotypes. Furthermore, robust and functional CD4(+) and CD8(+) cytotoxic T lymphocytes (CTL) were generated. LV, however, induced only weak memory responses. Thus, this study allows an improved understanding of the pathogenesis and immune mechanisms involved in the control of human LV.
Collapse
Affiliation(s)
- Delphine Pannetier
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon Cedex 07, France.
| | | | | | | | | | | | | |
Collapse
|
16
|
Baize S, Pannetier D, Faure C, Marianneau P, Marendat I, Georges-Courbot MC, Deubel V. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect 2006; 8:1194-202. [PMID: 16621649 DOI: 10.1016/j.micinf.2006.02.002] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2005] [Revised: 02/08/2006] [Accepted: 02/10/2006] [Indexed: 01/12/2023]
Abstract
Lassa fever is a hemorrhagic fever caused by Lassa virus (LV), which primarily targets human dendritic cells (DC) and macrophages (MP). Massive numbers of viral particles are released with no effect on the viability, activation or maturation of these cells. LV does not inhibit the activation of cells induced by sCD40L or LPS. We report here the consequences of exogenous activation of LV-infected human DC and MP for viral replication. The activation of cells with lipopolysaccharide or exogenous poly(I-C) and the transfection of cells with poly(I-C) strongly inhibited LV replication, at least partly by inducing type I interferon (IFN) synthesis. In contrast, cell stimulation with sCD40L did not induce type I IFN responses or inhibit LV release. Recombinant type I IFNs strongly inhibited LV replication in both cell types, whereas IFNgamma and IFNlambda did not. The modest type I IFN production observed in LV-infected MP, but not in DC, was involved in controlling LV replication in MP. These results provide an explanation for the slower replication of LV in MP than in DC, and suggest that type I IFNs are crucial in the control of LV.
Collapse
Affiliation(s)
- Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Laboratoire P4-Jean Mérieux, Institut Pasteur-IFR-128, Biosciences Lyon-Gerland, 21 Avenue Tony Garnier, 69365 Lyon Cedex 07, France.
| | | | | | | | | | | | | |
Collapse
|
17
|
Pannetier D, Faure C, Georges-Courbot MC, Deubel V, Baize S. Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J Virol 2004; 78:10516-24. [PMID: 15367618 PMCID: PMC516411 DOI: 10.1128/jvi.78.19.10516-10524.2004] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Lassa virus (LV) and Mopeia virus (MV) are closely related members of the Arenavirus genus, sharing 75% amino acid sequence identity. However, LV causes hemorrhagic fever in humans and nonhuman primates, whereas MV cannot induce disease. We have previously shown that antigen-presenting cells (APC)-macrophages (MP) and dendritic cells (DC)-sustain high replication rates of LV but are not activated, suggesting that they play a role in the immunosuppression observed in severe cases of Lassa fever. Here, we infected human APC with MV and analyzed the cellular responses induced. MV infection was productive in MP and even more so in DC. Apoptosis was not induced in either cell type. Moreover, unlike DC, MP were early and strongly activated in response to MV, as shown by the increased surface expression of CD86, CD80, CD54, CD40, and HLA-abc and by the production of mRNA encoding alpha interferon (IFN-alpha), IFN-beta, tumor necrosis factor alpha and interleukin-6. In addition, MV-infected MP produced less of the virus than DC, which was related to the fact that these cells secreted IFN-alpha. Thus, the strong activation of MP is probably a major event in the control of MV infection and may be involved in the induction of an adaptive immune response in infected hosts. These results may explain the difference in pathogenicity between LV and MV.
Collapse
Affiliation(s)
- Delphine Pannetier
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur-IFR 128 Biosciences Lyon-Gerland, Lyon, France
| | | | | | | | | |
Collapse
|
18
|
Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 2004; 172:2861-9. [PMID: 14978087 DOI: 10.4049/jimmunol.172.5.2861] [Citation(s) in RCA: 157] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Lassa fever is a hemorrhagic fever caused by Lassa virus (LV), an old-world Arenavirus. Little is known about the immune responses that occur during the disease, but protection seems to be linked to the induction of cellular responses specific for viral glycoproteins. Conversely, severe Lassa fever may be associated with immunosuppression. We studied the infection of human dendritic cells (DC) and macrophages (MP) by LV. Both these cell types are susceptible to LV infection. Viral nucleoprotein was detected in DC and MP, and high and moderate viral titers were obtained with culture supernatants of DC and MP, respectively. LV did not induce apoptosis in DC and MP. These cells were not activated by LV infection. No change was observed in the expression of surface molecules involved in activation, costimulation, adhesion, and Ag presentation following LV infection, or in the functional properties of DC. Inflammatory cytokine production was not detected at the mRNA or protein level after LV infection of DC and MP. Thus, MP, and particularly DC, are crucial targets for LV and are probably involved in the early replication of LV from the initial site of infection. The lack of activation and maturation of cells following infection may be associated with the immunosuppression observed in severe LV infection.
Collapse
Affiliation(s)
- Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Centre de Recherche Mérieux-Pasteur à Lyon, Laboratoire P4-Jean Mérieux, Lyon, France.
| | | | | | | | | | | |
Collapse
|
19
|
Yu MQ, Person-Dedryver F, Jahier J, Pannetier D, Tanguy AM, Abelard P. Resistance to root knot nematode, Meloidogyne naasi (Franklin) transferred from Aegilops variabilis Eig to bread wheat. ACTA ACUST UNITED AC 1990. [DOI: 10.1051/agro:19900603] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|